GOAL OF WORK: The aim of this study was to compare palifermin, a recombinant form of human keratinocyte growth factor, with standard treatment on outcomes in patients receiving a high dose of chemotherapy conditioning regimen, undergoing hematopoietic stem cell transplantation (HSCT). MATERIALS AND METHODS: Over a 1-year period, a series of 59 patients were included: 32 patients (palifermin) were compared with 27 patients (standard treatment). Outcomes assessed at day 8 posttransplantation were mucositis, swallowing, nutrition impact symptoms, dietary intake, time to engraftment, length of stay, infection, and cumulative dose and duration of narcotic administration. MAIN RESULTS: There was a significant reduction in the incidence of severe oral mucositis (13 vs 48%, p=0.003), swallowing problems (p=0.044), number of nutrition impact symptoms experienced (4.9 vs 6.0, p=0.003), and length of stay (14 vs 18 days, p=0.026) in the palifermin group compared to standard care. There was no significant difference in infection, dietary intake, time to engraftment or cumulative dose and duration of narcotic administration between groups. CONCLUSIONS: Beneficial outcomes were observed from the use of palifermin in patients undergoing HSCT after a high dose of chemotherapy conditioning regimen. A randomized clinical trial is needed to confirm these results.
RCT Entities:
GOAL OF WORK: The aim of this study was to compare palifermin, a recombinant form of humankeratinocyte growth factor, with standard treatment on outcomes in patients receiving a high dose of chemotherapy conditioning regimen, undergoing hematopoietic stem cell transplantation (HSCT). MATERIALS AND METHODS: Over a 1-year period, a series of 59 patients were included: 32 patients (palifermin) were compared with 27 patients (standard treatment). Outcomes assessed at day 8 posttransplantation were mucositis, swallowing, nutrition impact symptoms, dietary intake, time to engraftment, length of stay, infection, and cumulative dose and duration of narcotic administration. MAIN RESULTS: There was a significant reduction in the incidence of severe oral mucositis (13 vs 48%, p=0.003), swallowing problems (p=0.044), number of nutrition impact symptoms experienced (4.9 vs 6.0, p=0.003), and length of stay (14 vs 18 days, p=0.026) in the palifermin group compared to standard care. There was no significant difference in infection, dietary intake, time to engraftment or cumulative dose and duration of narcotic administration between groups. CONCLUSIONS: Beneficial outcomes were observed from the use of palifermin in patients undergoing HSCT after a high dose of chemotherapy conditioning regimen. A randomized clinical trial is needed to confirm these results.
Authors: Patrick J Stiff; Christos Emmanouilides; William I Bensinger; Teresa Gentile; Bruce Blazar; Thomas C Shea; John Lu; John Isitt; Alessandra Cesano; Ricardo Spielberger Journal: J Clin Oncol Date: 2006-01-03 Impact factor: 44.544
Authors: S T Sonis; G Oster; H Fuchs; L Bellm; W Z Bradford; J Edelsberg; V Hayden; J Eilers; J B Epstein; F G LeVeque; C Miller; D E Peterson; M M Schubert; F K Spijkervet; M Horowitz Journal: J Clin Oncol Date: 2001-04-15 Impact factor: 44.544
Authors: Stephen T Sonis; Linda S Elting; Dorothy Keefe; Douglas E Peterson; Mark Schubert; Martin Hauer-Jensen; B Nebiyou Bekele; Judith Raber-Durlacher; J Peter Donnelly; Edward B Rubenstein Journal: Cancer Date: 2004-05-01 Impact factor: 6.860
Authors: Edward B Rubenstein; Douglas E Peterson; Mark Schubert; Dorothy Keefe; Deborah McGuire; Joel Epstein; Linda S Elting; Philip C Fox; Catherine Cooksley; Stephen T Sonis Journal: Cancer Date: 2004-05-01 Impact factor: 6.860
Authors: Kim Robien; Mark M Schubert; Barbara Bruemmer; Michele E Lloid; John D Potter; Cornelia M Ulrich Journal: J Clin Oncol Date: 2004-04-01 Impact factor: 44.544
Authors: Helen V Worthington; Jan E Clarkson; Gemma Bryan; Susan Furness; Anne-Marie Glenny; Anne Littlewood; Martin G McCabe; Stefan Meyer; Tasneem Khalid Journal: Cochrane Database Syst Rev Date: 2011-04-13
Authors: Philip Riley; Anne-Marie Glenny; Helen V Worthington; Anne Littlewood; Luisa M Fernandez Mauleffinch; Jan E Clarkson; Martin G McCabe Journal: Cochrane Database Syst Rev Date: 2017-11-28
Authors: Paul Urbain; Anna Raynor; Hartmut Bertz; Christine Lambert; Hans-Konrad Biesalski Journal: Support Care Cancer Date: 2011-10-01 Impact factor: 3.603
Authors: Diana T Nguyen; Sepideh Shayani; Joycelynne Palmer; Andrew Dagis; Stephen J Forman; Joel Epstein; Ricardo Spielberger Journal: Support Care Cancer Date: 2015-03-21 Impact factor: 3.603
Authors: Judith E Raber-Durlacher; Inger von Bültzingslöwen; Richard M Logan; Joanne Bowen; Abdul Rahman Al-Azri; Hele Everaus; Erich Gerber; Jesùs Garcia Gomez; Bo G Pettersson; Yoshihiko Soga; Fred K L Spijkervet; Wim J E Tissing; Joel B Epstein; Sharon Elad; Rajesh V Lalla Journal: Support Care Cancer Date: 2012-09-18 Impact factor: 3.603
Authors: G Milone; S Leotta; A Cupri; A L Fauci; P Spina; M Parisi; D Berritta; G Tripepi Journal: Bone Marrow Transplant Date: 2014-07-07 Impact factor: 5.483
Authors: Karis Kin-Fong Cheng; S F Leung; Raymond H S Liang; Josepha W M Tai; Rebecca M W Yeung; David R Thompson Journal: Support Care Cancer Date: 2009-11-15 Impact factor: 3.603